Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Liver Cancer treatment details. Biologic therapy. Kantonsspital St. Gallen, St. Gallen, Switzerland

Survival: 9.3 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: Switzerland
City/State/Province: St. Gallen
Hospital: Kantonsspital St. Gallen
Journal: Link
Date: 3/2010

This phase II study involved 45 hepatocellular carcinoma patients who had not received prior systemic treatment. The median age was 63 years and 87% were male.

Patients were treated with the biologic therapy agent sunitinib, which is a tyrosine kinase inhibitor that interferes with cancer cell growth.

The highest reported toxicity level was grade 4 and included fatigue and anemia. The most common adverse events were anemia (grade 1-4), thrombocytopenia (grades 1-3), and fatigue (grade 1-4).

The median overall survival was 9.3 months.

This study was supported by Pfizer, Inc., makers of sunitinib (trade name: SUTENT).

Correspondence: Dr. Dieter Koeberle; email:

E-mail to a Friend Email Physician More Information